![Low dose mycophenolate mofetil versus cyclophosphamide in the induction therapy of lupus nephritis in Nepalese population: a randomized control trial | BMC Nephrology | Full Text Low dose mycophenolate mofetil versus cyclophosphamide in the induction therapy of lupus nephritis in Nepalese population: a randomized control trial | BMC Nephrology | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs12882-018-0973-7/MediaObjects/12882_2018_973_Fig1_HTML.png)
Low dose mycophenolate mofetil versus cyclophosphamide in the induction therapy of lupus nephritis in Nepalese population: a randomized control trial | BMC Nephrology | Full Text
![Frontiers | High-Dose Cyclophosphamide Administration Orchestrates Phenotypic and Functional Alterations of Immature Dendritic Cells and Regulates Th Cell Polarization Frontiers | High-Dose Cyclophosphamide Administration Orchestrates Phenotypic and Functional Alterations of Immature Dendritic Cells and Regulates Th Cell Polarization](https://www.frontiersin.org/files/Articles/548602/fphar-11-00775-HTML/image_m/fphar-11-00775-g001.jpg)
Frontiers | High-Dose Cyclophosphamide Administration Orchestrates Phenotypic and Functional Alterations of Immature Dendritic Cells and Regulates Th Cell Polarization
Low-dose metronomic cyclophosphamide complements the actions of an intratumoral C-class CpG TLR9 agonist to potentiate innate immunity and drive potent T... | Oncotarget
![A Controlled Trial of Cyclophosphamide in Rheumatoid Arthritis — Cooperating Clinics Committee of the American Rheumatism Association | NEJM A Controlled Trial of Cyclophosphamide in Rheumatoid Arthritis — Cooperating Clinics Committee of the American Rheumatism Association | NEJM](https://www.nejm.org/na101/home/literatum/publisher/mms/journals/content/nejm/1970/nejm_1970.283.issue-17/nejm197010222831701/20130816/images/img_medium/nejm197010222831701_t2.jpeg)
A Controlled Trial of Cyclophosphamide in Rheumatoid Arthritis — Cooperating Clinics Committee of the American Rheumatism Association | NEJM
![IJMS | Free Full-Text | Low Dose Cyclophosphamide Modulates Tumor Microenvironment by TGF-β Signaling Pathway IJMS | Free Full-Text | Low Dose Cyclophosphamide Modulates Tumor Microenvironment by TGF-β Signaling Pathway](https://www.mdpi.com/ijms/ijms-21-00957/article_deploy/html/images/ijms-21-00957-g001-550.jpg)
IJMS | Free Full-Text | Low Dose Cyclophosphamide Modulates Tumor Microenvironment by TGF-β Signaling Pathway
![Combination treatment with rituximab, low-dose cyclophosphamide and plasma exchange for severe antineutrophil cytoplasmic antibody-associated vasculitis - ScienceDirect Combination treatment with rituximab, low-dose cyclophosphamide and plasma exchange for severe antineutrophil cytoplasmic antibody-associated vasculitis - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0085253821008590-fx1.jpg)
Combination treatment with rituximab, low-dose cyclophosphamide and plasma exchange for severe antineutrophil cytoplasmic antibody-associated vasculitis - ScienceDirect
![Metronomic oral cyclophosphamide in relapsed ovarian cancer | International Journal of Gynecologic Cancer Metronomic oral cyclophosphamide in relapsed ovarian cancer | International Journal of Gynecologic Cancer](https://ijgc.bmj.com/content/ijgc/31/7/1037/F1.large.jpg)
Metronomic oral cyclophosphamide in relapsed ovarian cancer | International Journal of Gynecologic Cancer
![Dosing of mesna to avoid urothelial toxicity from cyclophosphamide infusion - Journal of Prescribing Practice Dosing of mesna to avoid urothelial toxicity from cyclophosphamide infusion - Journal of Prescribing Practice](https://www.prescribingpractice.com/media/bp5fx5du/calculation_16_1000x667.jpg)
Dosing of mesna to avoid urothelial toxicity from cyclophosphamide infusion - Journal of Prescribing Practice
![Substitution of Oral for Intravenous Cyclophosphamide in Membranous Nephropathy | American Society of Nephrology Substitution of Oral for Intravenous Cyclophosphamide in Membranous Nephropathy | American Society of Nephrology](https://kidney360.asnjournals.org/content/kidney360/1/9/943/F1.large.jpg)
Substitution of Oral for Intravenous Cyclophosphamide in Membranous Nephropathy | American Society of Nephrology
![Low-Dose Oral Cyclophosphamide and Methotrexate Maintenance for Hormone Receptor–Negative Early Breast Cancer: International Breast Cancer Study Group Trial 22-00 | Journal of Clinical Oncology Low-Dose Oral Cyclophosphamide and Methotrexate Maintenance for Hormone Receptor–Negative Early Breast Cancer: International Breast Cancer Study Group Trial 22-00 | Journal of Clinical Oncology](https://ascopubs.org/na101/home/literatum/publisher/asco/journals/content/jco/2016/jco.2015.64.34.issue-28/jco.2015.65.6595/20161107/images/medium/jco656595t2.gif)
Low-Dose Oral Cyclophosphamide and Methotrexate Maintenance for Hormone Receptor–Negative Early Breast Cancer: International Breast Cancer Study Group Trial 22-00 | Journal of Clinical Oncology
![High exposures to bioactivated cyclophosphamide are related to the occurrence of veno-occlusive disease of the liver following high-dose chemotherapy | British Journal of Cancer High exposures to bioactivated cyclophosphamide are related to the occurrence of veno-occlusive disease of the liver following high-dose chemotherapy | British Journal of Cancer](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fsj.bjc.6603097/MediaObjects/41416_2006_Article_BF6603097_Fig1_HTML.gif)
High exposures to bioactivated cyclophosphamide are related to the occurrence of veno-occlusive disease of the liver following high-dose chemotherapy | British Journal of Cancer
![Journal of Prescribing Practice - Dosing of mesna to avoid urothelial toxicity from cyclophosphamide infusion Journal of Prescribing Practice - Dosing of mesna to avoid urothelial toxicity from cyclophosphamide infusion](https://www.prescribingpractice.com/media/qi5p2ayx/jprp-2022-4-8-342_f01.jpg)